Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome

Anavex Reports Fiscal First Quarter 2015 Financial Results

February 18, 2015

Amarantus Announces First Alzheimer’s Biomarker Services Collaboration for LymPro Test® with Anavex Life Sciences Corp.

February 18, 2015

Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases

February 9, 2015

Anavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th

February 4, 2015

Mitochondrial protection by the mixed muscarinic/sigma-1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Ab25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model.

January 20, 2015

Anavex Doses First Alzheimer’s Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS

January 12, 2015

Anavex Announces Panel Discussion and Presentation at OneMedForum Conference

January 8, 2015

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor

January 6, 2015

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

December 30, 2014

Anavex to Present at Biotech Showcase 2015 in San Francisco

December 18, 2014

Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

December 16, 2014

Anavex Upgrades to OTCQX Marketplace

December 12, 2014
1
2345678910111213141516171819
…2021222324…
252627282930313233343536373839404142
43

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top